01 Robust and Internationally Aligned Regulatory Environment

Hong Kong operates a transparent and internationally recognized clinical trial regulatory system supervised by the Department of Health and the Pharmacy and Poisons Board of Hong Kong (PPBHK). Clinical trials must comply with ICH‑GCP standards and local legislation under the Pharmacy and Poisons Ordinance (Cap.138), ensuring high data credibility and global acceptability.

02 World‑Class Healthcare Infrastructure and Trial Capability

Hong Kong's public healthcare system, managed by the Hospital Authority (HA), covers around 90% of inpatient services and provides a territory‑wide, standardised clinical environment ideal for multi‑centre trials. HA hospitals maintain strong research governance, experienced investigators, and integrated electronic medical record systems.

03 High‑Quality Population Data and Real‑World Evidence Access

Hong Kong offers exceptional access to population‑level health data through official platforms operated by the Hospital Authority, Department of Health, and Census and Statistics Department. Initiatives such as the HA Data Sharing Portal and HKSTP–HA Data Collaboration Lab provide controlled access to anonymised clinical data from approximately 200,000 patients, enabling feasibility assessments, external control arms, and real‑world evidence (RWE) generation.

04 Strategic Location and Gateway to the Greater Bay Area (GBA)

Hong Kong's unique position under “One Country, Two Systems” enables it to serve as a super‑connector between global sponsors and Mainland China. Through government‑led initiatives such as the Greater Bay Area International Clinical Trial Institute (GBAICTI) and the GBA Clinical Trial Collaboration Platform, Hong Kong facilitates cross‑boundary patient access, investigator collaboration, and data integration.

01 Diverse Patient Pool

With nearly 100 million people, Vietnam offers a treatment-naive population across diverse ethnic groups, ensuring high adherence and robust enrollment data for global trials.

02 Operational Excellence

Competitive operational costs are paired with a highly skilled workforce. Vietnamese medical professionals are increasingly trained in ICH-GCP standards to support complex studies.

01 Cost-Effective Research Environment

Thailand provides a cost-effective platform for conducting clinical trials, with lower operational costs compared to many Western countries. This includes competitive salaries for medical staff, affordable infrastructure, and access to modern facilities. As a result, multinational pharmaceutical companies continue to be attracted to Thailand as a strategic location for their research activities, particularly in areas such as oncology, cardiology, and rare diseases.

02 Highly Qualified Medical Professionals

Thailand is home to a large number of well-trained doctors, clinical trial coordinators, and researchers who are proficient in Good Clinical Practice (GCP). Many professionals have received training both locally and abroad, ensuring a high level of expertise and adherence to global standards. This skilled workforce contributes to the successful execution of clinical trials and enhances the overall quality of research conducted in the country.

01 Established and Internationally Recognised Regulatory Environment

Malaysia offers a well-structured and internationally aligned clinical trial regulatory framework overseen by the National Pharmaceutical Regulatory Agency (NPRA) and Medical Research & Ethics Committee (MREC). Clinical trials are conducted in compliance with ICH-GCP standards and local regulations under the Control of Drugs and Cosmetics Regulations 1984, ensuring high-quality data, subject protection, and global regulatory acceptability.

02 Diverse Patient Population and Strong Investigator Network

Malaysia’s multi-ethnic population comprising Asian, Malay, Chinese, Indian, and indigenous communities provides access to genetically and culturally diverse patient populations. The country is supported by experienced investigators across public and private hospitals with strong recruitment capabilities in oncology, infectious diseases, metabolic disorders, vaccines, and rare diseases, enabling efficient enrolment and high-quality trial conduct.

03 Cost-Effective Operations with High-Quality Healthcare Infrastructure

Malaysia provides a cost-efficient clinical trial environment without compromising quality. The country has modern healthcare infrastructure, internationally accredited hospitals, central laboratories, and advanced diagnostic capabilities. English is widely used in medical practice and documentation, facilitating seamless communication with global sponsors and CROs while maintaining competitive operational costs compared with Western markets and several Asia-Pacific countries.

04 Strategic Gateway to Southeast Asia

Located in the heart of Southeast Asia, Malaysia serves as a strategic regional hub with strong connectivity across ASEAN countries. Its stable business environment, well-developed logistics network, and growing clinical research ecosystem make it an attractive destination for regional and multi-country studies. Malaysia also offers access to both urban and regional patient populations, supporting broader feasibility and real-world applicability of clinical trial outcomes.

01 Scalable Patient Access and Recruitment Power

With a population of over 287 million people, Indonesia offers one of the largest and most scalable patient pools globally, enabling efficient enrollment for large and diverse clinical programs. 

02 Expanding Clinical Research Momentum

Indonesia’s clinical trial landscape is rapidly advancing, supported by growing investigator experience, increasing site readiness, and rising participation in global multicenter studies, particularly in vaccines and chronic diseases.

03 Navigable Regulatory Pathways with Planning Advantage

A structured regulatory framework led by BPOM provides clear submission pathways, while early planning around sequential approvals, import licensing, and sample export processes enables predictable study execution. 

04 Reliable Delivery with Broad Site Coverage

Strong operational expertise, combined with a wide network of referral hospitals and experienced investigators across major cities, supports consistent delivery of Phase I–III trials with high data quality and execution efficiency.

01 Large and Diverse Patient Pool

Accessible Population: With a population exceeding 113 million (12th most populous in the world), the country provides a vast, diverse pool of potential participants.
Treatment-Naïve Patients: A large proportion of the population has limited prior exposure to investigational or branded therapies, making it an ideal location for collecting clean data, especially for metabolic, oncology, and infectious disease studies.
High Birth Rate: This supports strong enrollment opportunities for pediatric and maternal health studies

02 Streamlined Regulatory Environment

Rapid Approvals: The Philippine Food and Drug Administration (FDA) has streamlined processes, with regulatory reliance guidelines aiming for approval timelines as short s 20-30 working days for eligible studies
Ethics Review Boards: There are over 46 accredited Ethics Review Boards (ERBs) to ensure swift protocol reviews.
Modernized Frameworks: The regulatory landscape now aligns with ICH-GCP guidelines with a focus on implementing digital, patient-centric and decentralized trial methodologies.

03 Rapid Patient Recruitment

High Enrollment Rates: The Philippines is known for fast, efficient recruitment, with some trials achieving over 9,000 subjects in just two months.

Strong Network: There is an established network of over 200 experienced, international-standard clinical trial sites and investigators, primarily in Metro Manila, Cebu, Davao and Iloilo..

04 High-Quality Research Standards

Proven Compliance: Inspections by international bodies, including the US FDA, Japanese PMDA, and Chinese regulatory authorities, have consistently yielded high quality with no major warning letters.

Trained Workforce: The Philippines boasts a high literacy rate and widespread English fluency, with many investigators trained in Western medicine and research practices.

05 Cost-effectiveness

Lower Trial Costs: Running trials in the Philippines can be approximately 60% lower than in the US and 20–30% lower than in Western European countries.

Competitive Investigator Fees: Phase III trial investigator site fees are highly competitive, enhancing the ROI for sponsors.

06 Strategic Focus on Key Therapeutic Areas

Prevalent Diseases: The country has a strong track record in researching chronic diseases that correlate with local demographics, including Type 2 diabetes, cardiovascular diseases, oncology (breast and lung cancer), infectious diseases (tuberculosis, dengue, COVID-19), and respiratory disorders.

07 Strategic Government Support

Incentives and Growth: The government, through the Department of Science and Technology (DOST-PCHRD), strongly supports clinical research, promoting it as part of the country's "Four Futures of Health" (Personalized, Preventive, Predictive, and Participatory).
Emerging Biotech Hub: By 2026, the biotech industry in the Philippines is expected to gain significant momentum in clinical trial outsourcing and partnerships, positioning the country as a regional hotspot.